TOKYO, April 10. /TASS/. Takeda Pharmaceutical has suspended new clinical trials of drugs in Russia due to the situation around Ukraine, Nikkei newspaper reports on Sunday.
The company will also halt new investments in Russia. Supplies of drugs and clinical trials will continue. Sanctions against Russia linked to its special military operation in Ukraine do not apply to the pharmaceutical business but introduced restrictions made logistics and transactions more challenging.
Astellas Pharma, another Japanese pharmaceutical company, also suspended enrollment new patients in Russia and Ukraine for clinical trials of their pharmaceuticals.
According to the report of the Japanese Office of Pharmaceutical Industry Research, Russia ranked 11th worldwide in 2019 in terms of international clinical trials held from 2000 to 2018. Experts believe that the trend of halting pharmaceutical trials in Russia may lead to delays in developing new medications.